Immunotherapy for medullary thyroid carcinoma by dendritic cell vaccination

Journal of Clinical Endocrinology and Metabolism

Volumn 86, Issue 10, 2001, Pages 4965-4969

  Schott, Matthias ^a   Seissler, Jochen ^a   Lettmann, Melanie ^a   Fouxon, Vladimir ^a   Scherbaum, Werner A ^a   Feldkamp, Joachim ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIGEN SPECIFICITY; ARTICLE; CALCITONIN BLOOD LEVEL; CANCER REGRESSION; CELLULAR IMMUNITY; CLINICAL ARTICLE; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; DRUG EFFECT; DRUG EFFICACY; FEMALE; FEVER; FOLLOW UP; HUMAN; IMMUNOTHERAPY; LIVER METASTASIS; MALE; MEMORY CELL; METASTASIS; MONOCYTE; PRIORITY JOURNAL; THYROID MEDULLARY CARCINOMA;

EID: 0034750683     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.86.10.7949     Document Type: Article

References (26)

1. Medullary thyroid carcinoma: Clinical characteristics, treatment, prognostic factors, and a comparison of staging systems
2. Progression of postoperative residual medullary thyroid carcinoma as monitored by plasma calcitonin levels
3. Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma
4. The dendritic cell system and its role in immunogenicity
5. Mature dendritic cells boost functionally superior CD8(+) T-cell in humans without foreign helper epitopes
6. High levels of a major histocompatibility complex II-self peptide complex on dendritic cells from the T cell areas of lymph nodes
7. B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells
8. The tissue distribution of the B7-2 costimulator in mice: Abundant expression on dendritic cells in situ and during maturation in vitro
9. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
10. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
11. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells
12. Follow-up evaluation of a phase II prostate cancer vaccine trial
13. Higher-dose and less frequent dendritic cell infusions with PSMA peptides in hormone-refractory metastatic prostate cancer patients
14. Vaccination of patients with B-cell lymphoma using autologous antigen- pulsed dendritic cells
15. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells
16. Mature dendritic cells induce T-helper type-1-dominant immune responses in patients with metastatic renal cell carcinoma
17. Dendritic cell immunotherapy in disseminated parathyroid carcinoma
18. Dendritic cell immunotherapy induces antitumour response in parathyroid carcinoma and neuroendocrine pancreas carcinoma
19. Induction of cellular immunity in a parathyroid carcinoma treated with tumor lysate-pulsed dendritic cells
20. Phase I/II trial of (131)I-MN-14F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma
21. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine
22. Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2
23. Immunotherapy of cancer. Generation of CEA specific CTL using CEA peptide pulsed dendritic cells
24. Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA
25. Induction of a cellular and humoral immune response against preprocalcitonin by genetic immunization: A potential new treatment for medullary thyroid carcinoma
26. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids